Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model

Eye

Volumn 23, Issue 1, 2009, Pages 132-140

  Stewart, W C ^a,b,d   Stewart, J A ^a   Mychaskiw, M A ^c  

^a University of South Carolina   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c PFIZER INC   (United States)

^d NONE   (United States)

Author keywords

Cost; Latanoprost; Markov; Timolol

Indexed keywords

LATANOPROST; TIMOLOL MALEATE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; EXFOLIATION SYNDROME; HUMAN; MEDICAL LITERATURE; MEDICAL PRACTICE; OPEN ANGLE GLAUCOMA; SCANDINAVIA; UNITED KINGDOM;

EID: 58249111549     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702964     Document Type: Article

References (65)

1. Day DG, Schacknow PN, Sharpe ED, Ellyn JC, Kulze JC, Threlkeld AB et al. A persistency and economic analysis of latanoprost, bimatoprost or beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2004; 20: 383-392.
2. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004; 137: S3-S12.
3. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 2004; 137: S13-S16.
4. Sherwood M, Brandt J, Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001; 45: S361-S368.
5. Netland PA, Landry T, Sullivan K, Andrew R, Silver L, Weiner A et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 472-484.
6. Zhang WY, Po AL, Dua HS, Azuara-Blanco A. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 2001; 85: 983-990.
7. Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol 2002; 47: S77-S89.
8. Rychlik R. Strategies in Pharmacoeconomics and Outcomes Research. Hayworth Press Inc.: Binghampton, NY, 2002.
9. Le Pen C, Ligier M, Berdeaux G. Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom. J Med Econ 2005; 8: 67-84.
10. Nordmann JP, Lafuma A, Deschaseaux C, Berdeaux G. Clinical outcomes of glaucoma treatments over a patient lifetime: a Markov model. J Glaucoma 2005; 14: 463-469.
11. Christensen TL, Poulsen PB, Holmstrom S, Walt JG, Vetrugno M. A Markov modeled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy. Curr Med Res Opin 2005; 21: 1837-1844.
12. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991; 111: 51-55.
13. Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 1993; 116: 176-181.
14. Stewart WC, Kolker AE, Sharpe ED, Day DG, Holmes KT, Leech JN et al. Factors associated with long-term progression or stability in primary open-angle glaucoma. Am J Ophthalmol 2000; 130: 274-279.
15. Konstas AG, Hollo G, Astakhov YS, Teus MA, Akopov EL, Jenkins JN et al. Factors associated with long-term progression or stability in exfoliation glaucoma. Arch Ophthalmol 2004; 122: 29-33.
16. Kobelt G, Jonsson B, Bergstrom A, Chen E, Linden C, Alm A. Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand 2006; 84: 363-371.
17. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38: 583-637.
18. Blika S, Ringvold A. The occurrence of simple and capsular glaucoma in Middle-Norway. Acta Ophthalmol Scan Suppl 1987; 182: S11-S16.
19. Ringvold A, Blika S, Elsas T, Guldahl J, Brevik T, Hesstvedt P et al. The middle-Norway eye-screening study. II. Prevalence of simple and capsular glaucoma. Acta Ophthalmol (Copenh) 1991; 69: 273-280.
20. Lindblom B, Thorburn W. Observed incidence of glaucoma in Halsingland, Sweden. Acta Ophthalmol (Copenh) 1984; 62: 217-222.
21. Grodum K, Heijl A, Bengtsson B. A comparison of glaucoma patients identified through mass screening and in routine clinical practice. Acta Ophthalmol Scan 2002; 80: 627-631.
22. Ekstrom C. Elevated intraocular pressure and pseudoexfoliation of the lens capsule as risk factors for chronic open-angle glaucoma. A population-based five-year follow-up study. Acta Ophthalmol (Copenh) 1993; 71: 189-195.
23. Ohrt V, Hehen JH. The incidence of glaucoma capsulare based on a Danish hospital material. Acta Ophthalmol Scand 1981; 59: 888-893.
24. Alyahya GA, Hietanen J, Heegaard S, Kivela T, Prause JU. Exfoliation syndrome in Nordic countries: a comparative histopathological study of Danish and Finnish eyes with absolute glaucoma and uveal melanoma. Acta Ophthalmol Scand 2005; 83: 711-715.
25. Aasved H. Prevalence of fibrillopathia epitheliocapsularis (pseudoexfoliation) and capsular glaucoma. Trans Ophthalmol Soc UK 1979; 99: 293-295.
26. Aasved H. The geographical distribution of fibrillopathia epitheliocapsularis, so-called senile exfoliation or pseudoexfoliation of the anterior lens capsule. Acta Ophth (Copenh) 1969; 47: 792-810.
27. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003; 135: 55-63.
28. Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002; 120: 1286-1293.
29. Cohen JS, Gross RL, Cheetham JK, VanDenburgh AM, Bernstein P, Whitcup SM. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004; 49: S45-S52.
30. Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003; 135: 688-703.
31. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol 2000; 10: 95-104.
32. Zhou Z, Althin R, Sforzolini BS, Dhawan R. Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom. Br J Ophthalmol 2004; 88: 1391-1394.
33. Dasgupta S, Oates V, Bookhart BK, Vaziri B, Schwartz GF, Mozaffari E. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care 2002; 8: S255-S261.
34. Spooner JJ, Bullano MF, Ikeda LI, Cockerham TR, Waugh WJ, Johnson T et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care 2002; 8: S262-S270.
35. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther 2003; 25: 1172-1185.
36. The Fluorouracil Filtering Surgery Study Group. Five-year follow-up of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol 1996; 121: 349-366.
37. Rothman RF, Liebmann JM, Ritch R. Low-dose 5-fluorouracil trabeculectomy as initial surgery in uncomplicated glaucoma: long-term follow-up. Ophthalmology 2000; 107: 1184-1190.
38. Marquardt D, Lieb WE, Grehn F. Intensified postoperative care versus conventional follow-up: a retrospective long-term analysis of 177 trabeculectomies. Graefes Arch Clin Exp Ophthalmol 2004; 242: 106-113.
39. Wickham MG, Worthen DM. Argon laser trabeculotomy: long-term follow-up. Ophthalmology 1979; 86: 495-503.
40. Parrish II RK, Schiffman JC, Feuer WJ, Heuer DK, Fluorouracil Filtering Surgery Study Group. Prognosis and risk factors for early postoperative wound leaks after trabeculectomy with and without 5-fluorouracil. Am J Ophthalmol 2001; 132: 633-640.
41. Diestelhorst M, Khalili MA, Krieglstein GK. Trabeculectomy: a retrospective follow-up of 700 eyes. Int Ophthalmol 1998-99; 22: 211-220.
42. Pfeiffer N, European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002; 240: 893-899.
43. Chung PY, Schuman JS, Netland PA, Lloyd-Muhammad RA, Jacobs DS. Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. Am J Ophthalmol 1998; 126: 185-190.
44. Odberg T. Primary laser trabeculoplasty in glaucoma. A resource saving treatment. Tidsskr Nor Laegeforen 1990; 110: 3729-3730.
45. Spaeth GL, Baez KA. Argon laser trabeculoplasty controls one third of cases of progressive, uncontrolled, open angle glaucoma for 5 years. Arch Ophthalmol 1992; 110: 491-494.
46. Rosenberg T, Klie F. Current trends in newly registered blindness in Denmark. Acta Ophthalmol Scand 1996; 74: 395-398.
47. Fuchs J, Nissen KR, Goldschmidt E. Glaucoma blindness in Denmark. Acta Ophthalmol (Copenh) 1992; 70: 73-78.
48. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997; 38: 83-91.
49. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122: 477-485.
50. Chen PP. Blindness in patients with treated open-angle glaucoma. Ophthalmology 2003; 110: 726-733.
51. Hattenhauer MG, Johnson DH, Ing HH, Herman DC, Hodge DO, Yawn BP et al. The probability of blindness from open-angle glaucoma. Ophthalmology 1998; 105: 2099-2104.
52. Friedman DS, West SK, Munoz B, Park W, Deremeik J, Massof R et al. Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study. Arch Ophthalmol 2004; 122: 1019-1024.
53. Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol 2002; 86: 716-722.
54. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 2003; 87: 1201-1204.
55. Fiscella RG, Green A, Patuszynski DH, Wilensky J. Medical therapy cost considerations for glaucoma. Am J Ophthalmol 2003; 136: 18-25.
56. Mick AB, Gonzalez S, Dunbar MT, McSoley JJ. A cost analysis of the prostaglandin analogs. Optometry 2002; 73: 614-619.
57. Costagliola C, Parmeggiani F, Sebastiani A. Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension. Expert Opin Pharmacother 2003; 4: 1775-1788.
58. Stewart WC, Leech J, Sharpe ED, Kulze J, Ellyn J, Day DG. An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension. Am J Manag Care 2002; 8: S240-S248.
59. Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics 2006; 24: 251-264.
60. Noecker RJ, Walt JG. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. Am J Ophthalmol 2006; 141: S15-S21.
61. Tuil E, Hommer AB, Poulsen PB, Christensen TL, Buchholz P, Walt J et al. The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients - a European perspective. Int J Clin Pract 2005; 59: 1011-1016.
62. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. NICE: London, UK, 2004. 63 Alm A, Stjernschantz J, Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology 1995; 102: 1743-1752.
63. Camras CB, United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology 1996; 103: 138-147.
64. Watson P, Stjernschantz J, Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103: 126-137.
65. Stewart WC, Day DG, Sharpe ED, Dubiner HB, Holmes KT, Stewart JA. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Am J Ophthalmol 1999; 128: 692-696.